Ro Review
Best for: broadest GLP-1 formulary including Foundayo on day-one of launch
Ro is one of the largest direct-to-patient telehealth companies in the US and operates the most comprehensive obesity care formulary in the category — compounded semaglutide, brand-name Wegovy and Zepbound, and as of April 9 2026, Eli Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149/month for the lowest dose plus membership.
Medium confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Ro is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Ro prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Foundayo (lowest dose, cash pay) | brand | $149 |
✓ Pros
- •Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- •Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- •Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- •Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- •Both cash-pay and insurance-eligible options under one roof
✗ Cons
- •Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- •Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- •State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- •Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Ready to start with Ro?
Starting at $149/month. See current pricing and start your free consultation.
Sources & methodology
Our Ro review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Alternatives to Ro
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Ro?
Starting at $149/month. See current pricing and start your free consultation.